N-Methyl-1-(propan-2-yl)-1H-pyrazol-4-amine | 936940-09-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-Methyl-1-(propan-2-yl)-1H-pyrazol-4-amine
• 英文别名: N-methyl-1-propan-2-ylpyrazol-4-amine
• CAS: 936940-09-9
• 化学式: C₇H₁₃N₃
• 分子量: 139.2
• InChiKey: DEBSGISFDAOGSU-UHFFFAOYSA-N

物化性质

• 沸点：
  234.0±15.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  29.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933199090
• 危险性防范说明：
  P264,P280,P302+P352,P305+P351+P338,P332+P313,P337+P313,P362
• 危险性描述：
  H315,H319

文献信息

• [EN] SULFONYLUREA DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SULFONYLURÉE ET LEURS UTILISATIONS
  申请人：NODTHERA LTD

  公开号：WO2020249664A1

  公开（公告）日：2020-12-17

  The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式(I)化合物及其前药、药用可接受盐、药物组合物、使用方法和制备方法。所公开的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗炎症、自身炎症和自身免疫疾病以及癌症等炎症小体活性涉及的疾病。
• [EN] COMPOUNDS FOR INHIBITING OR DEGRADING ITK, COMPOSITIONS, COMPRISING THE SAME METHODS OF THEIR MAKING AND METHODS OF THEIR USE<br/>[FR] COMPOSÉS DESTINÉS À INHIBER OU DÉGRADER L'ITK, COMPOSITIONS LES COMPRENANT, LEURS PROCÉDÉS DE FABRICATION ET LEURS PROCÉDÉS D'UTILISATION
  申请人：NURIX THERAPEUTICS INC

  公开号：WO2022235715A1

  公开（公告）日：2022-11-10

  Provided herein are compounds for inhibiting and/or degrading IL-2 inducible T-cell kinase (ITK), compositions comprising the compounds, methods of making the same, and methods of their use for treating diseases or disorders including cancer, inflammatory, and autoimmune diseases.

  本文提供了用于抑制和/或降解IL-2诱导T细胞激酶（ITK）的化合物，包括这些化合物的组合物，制备这些化合物的方法，以及使用这些化合物治疗包括癌症、炎症和自身免疫疾病在内的疾病或疾病的方法。
• [EN] HETEROCYCLIC COMPOUND SERVING AS FGFR INHIBITOR AND APPLICATION THEREOF<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE SERVANT D'INHIBITEUR DE FGFR ET SON APPLICATION<br/>[ZH] 作为FGFR抑制剂的杂环化合物及其应用
  申请人：HAINAN SPARKLE THERAPEUTICS CO LTD

  公开号：WO2022206939A1

  公开（公告）日：2022-10-06

  提供了一类作为FGFR抑制剂的杂环化合物，具体公开了式(I)所示化合物、其立体异构体或药学上可接受的盐，
• NOVEL IMIDAZOPYRIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING CANCER
  申请人：Daegu-Gyeongbuk Medical Innovation Foundation

  公开号：EP3473624A1

  公开（公告）日：2019-04-24

  The present invention relates to a novel imidazopyridine derivative, a method for preparing the same, and a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. The novel imidazopyridine derivative according to the present invention, a stereoisomer thereof and a pharmaceutically acceptable salt thereof can effectively inhibit cancer-related kinases, are excellent in inhibiting proliferation of cancer cells in a cancer cell line, and effectively inhibit proliferation of cancer cells (cancer cell apoptosis) in a cancer cell heterograft model, and thus can be useful as a pharmaceutical composition containing the same as an active ingredient for preventing or treating cancer. Also, the novel imidazopyridine derivative according to the present invention, the stereoisomer thereof, and the pharmaceutically acceptable salt thereof can effectively inhibit Src and Fyn, thereby being useful as a pharmaceutical composition for preventing or treating the Src and Fyn related diseases, and in particular, have been confirmed to be useful in diabetic nephropathy in animal model experiments. Therefore, the compound of the present invention can be effective as a pharmaceutical composition containing the same as an active ingredient for preventing or treating diabetic nephropathy.

  本发明涉及一种新型咪唑吡啶衍生物、其制备方法以及一种含有该衍生物作为有效成分的预防或治疗癌症的药物组合物。根据本发明的新型咪唑吡啶衍生物、其立体异构体和其药学上可接受的盐可有效抑制癌症相关激酶，在抑制癌细胞系中的癌细胞增殖方面表现出色，并可有效抑制癌细胞异种移植模型中的癌细胞增殖（癌细胞凋亡），因此可作为含有其作为活性成分的药物组合物用于预防或治疗癌症。 另外，根据本发明的新型咪唑吡啶衍生物、其立体异构体及其药学上可接受的盐可以有效抑制 Src 和 Fyn，从而可作为药物组合物用于预防或治疗与 Src 和 Fyn 相关的疾病，特别是已在动物模型实验中证实可用于糖尿病肾病。因此，本发明的化合物作为一种含有相同活性成分的药物组合物，可有效预防或治疗糖尿病肾病。
• [EN] ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASE<br/>[FR] DÉRIVÉ ARYLIQUE OU HÉTÉROARYLIQUE, ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT EN TANT QUE PRINCIPE ACTIF POUR LA PRÉVENTION OU LE TRAITEMENT D'UNE MALADIE ASSOCIÉE À UNE KINASE<br/>[KO] 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 예방 또는 치료용 약학적 조성물
  申请人：VORONOIBIO CO LTD

  公开号：WO2022015051A1

  公开（公告）日：2022-01-20

  아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물에 관한 것으로, 본 발명의 일 측면에서 제공하는 아릴 또는 헤테로아릴 유도체는 키나아제, 특히 RIPK1(Receptor-interacting serine/threonine-protein kinase 1)에 대해 우수한 억제 활성을 나타내므로, RIPK1 관련 질환의 치료제로 사용 가능하다.